• 제목/요약/키워드: $^{18}F$-fluorodeoxyglucose

검색결과 124건 처리시간 0.055초

F-18 fluorodeoxyglucose positron emission tomography/computed tomography in the infection of heart

  • Kong, Eunjung
    • Journal of Yeungnam Medical Science
    • /
    • 제38권2호
    • /
    • pp.95-106
    • /
    • 2021
  • Infections involving the heart are becoming increasingly common, and a timely diagnosis of utmost importance, despite its challenges. F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is a recently introduced diagnostic tool in cardiology. This review focuses on the current evidence for the use of FDG PET/CT in the diagnosis of infective endocarditis, cardiac implantable device infection, left ventricular assist device infection, and secondary complications. The author discusses considerations when using FDG PET/CT in routine clinical practice, patient preparation for reducing physiologic myocardial uptake, acquisition of images, and interpretation of PET/CT findings. This review also functions to highlight the need for a standardized acquisition protocol.

Preoperative Nodal 18F-FDG Avidity Rather than Primary Tumor Avidity Determines the Prognosis of Patients with Advanced Gastric Cancer

  • Kwon, Hyun Woo;An, Liang;Kwon, Hye Ryeong;Park, Sungsoo;Kim, Sungeun
    • Journal of Gastric Cancer
    • /
    • 제18권3호
    • /
    • pp.218-229
    • /
    • 2018
  • Purpose: This study investigated whether the metabolic avidity of primary tumors and/or metastatic lymph nodes (LNs) measured by $^{18}F$-fluorodeoxyglucose ($^{18}F-FDG$) positron emission tomography/computed tomography (PET/CT) was related to survival after surgery in patients with advanced gastric cancer (AGC). Materials and Methods: One hundred sixty-eight patients with AGC who underwent preoperative $^{18}F-FDG$ PET/CT and curative resection were included. The $^{18}F-FDG$ avidity of the primary gastric tumor and LNs was determined quantitatively and qualitatively. The diagnostic performance of $^{18}F-FDG$ PET/CT was calculated, and the prognostic significance of $^{18}F-FDG$ avidity for recurrence-free survival (RFS) and overall survival (OS) was assessed. Results: In all, 51 (30.4%) patients experienced recurrence, and 32 (19.0%) died during follow-up (median follow-up duration, 35 months; range, 3-81 months); 119 (70.8%) and 33 (19.6%) patients showed $^{18}F-FDG$-avid primary tumors and LNs, respectively. $^{18}F-FDG$ PET/CT showed high sensitivity (73.8%) for the detection of advanced pathologic T ($pT{\geq}3$) stage and high specificity (92.2%) for the detection of advanced pN (${\geq}2$) stage. $^{18}F-FDG$ avidity of LNs was significantly associated with RFS (P=0.012), whereas that of primary tumors did not show significance (P=0.532). Univariate and multivariate analyses revealed that $^{18}F-FDG$ avidity of LNs was an independent prognostic factor for RFS (hazard ratio=2.068; P=0.029). Conclusions: $^{18}F-FDG$ avidity of LNs is an independent prognostic factor for predicting RFS. Preoperative $^{18}F-FDG$ PET/CT can be used to determine the risk and prognosis of patients with AGC after curative resection.

비소세포 폐암의 병기 결정에서 F-18 FDG PET의 역할 (The Role of PET in Staging Non-Small Cell Lung Cancer)

  • 현인영
    • 대한핵의학회지
    • /
    • 제38권6호
    • /
    • pp.481-485
    • /
    • 2004
  • Lung cancer has become a leading cause of cancer death in Korea. Accurate staging of non-small cell lung cancer (NSCLC) is essential to the ability to offer a patient the most effective available treatment and the best estimate of prognosis. PET with F-18 fluorodeoxyglucose (FDG) is indicated for the nodal staging of NSCLC and detection of distant metastases. Use of PET for mediastinal staging should not be relied on as a sole staging modality, and positive findings should be confirmed by mediastinoscopy. FDG PET avoids futile surgery by a more accurate selection of patients, especially by the detection of unexpected distant metastases.

Application of Differential Expression of Genetic Profiles in Brain Tumors with Variable [$^{18}F$]-fluorodeoxyglucose Uptake

  • Lee, Seung-Ho;Yun, Mi-Jin;Kim, Ki-Nam;Seo, Sang-Hui;Sohn, Sung-Hwa;Kim, Yu-Ri;Kim, Hye-Won;Kim, In-Kyoung;Shim, Boo-Im;Lee, Seung-Min;Kim, Meyoung-Kon
    • Molecular & Cellular Toxicology
    • /
    • 제3권3호
    • /
    • pp.198-207
    • /
    • 2007
  • [ $^{18}F$ ]-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) scan has been found to reflect tumor aggressiveness and prognosis in various types of cancer. In this study, the gene expression profiles of glial tumors were evaluated to determine whether glial tumors with high $^{18}F$-FDG uptake have more aggressive biological potential than with low uptake. Surgical specimens were obtained from the 12 patients with glial tumors (4 males and 8 females, age range 42-68 years). The tumor samples were divided into two groups based on the $^{18}F$-FDG uptake PET scan findings: high $^{18}F$-FDG uptake (n=4) and low $^{18}F$-FDG uptake (n=8). The pathological tumor grade was closely correlated with the $^{18}F$-FDG uptake pattern: Glial tumors with high $^{18}F$-FDG uptake were pathologically Edmondson-Steiner grade III, while those with low uptake were grade II. The total RNA was extracted from the frozen tissues of all glial tumors (n=12), and adjacent non-cancerous tissue (n=3). The gene expression profiles were evaluated using cDNA microarray. The glial tumors with high $^{18}F$-FDG uptake showed increase expression of 15 genes compared to those with low uptake (P<0.005). Nine genes were down-regulated. Gene expression is closely related to cell survival, cell-to-cell adhesion or cell spreading; therefore, glial tumors with high $^{18}F$-FDG uptake appear to have more aggressive biological properties than those with low uptake.

신경섬유종증 환자의 F-18 FDG PET/CT에서 육종전환으로 오인된 신경섬유종 (A Neurofibroma Confused with Sarcomatous Transformation on F-18 FDG PET/CT in Neurofibromatosis-1)

  • 박순아;송정훈;양충용;김헌수;박승철
    • Nuclear Medicine and Molecular Imaging
    • /
    • 제43권4호
    • /
    • pp.361-362
    • /
    • 2009
  • We present a patient with high $^{18}$F-fluorodeoxyglucose (FDG) uptake detected in a neurofibroma that was confused with sarcomatous transformation on a positron emission tomography/computed tomography (PET/CT) scan. A 39-year-old male patient with a 20-year history of neurofibromatosis-1 (NF-1) performed FDG PET/CT scan for the evaluation of lesions with sarcomatous transformation. The FDG PET/CT images demonstrated varying degrees of increased FDG uptake in the multiple nodules throughout whole body. The left pelvic mass with the highest FDG uptake had a maximum standardized uptake values (maxSUV) 5.0 and surgical resection was performed. Histological analysis confirmed the presence of a benign neurofibroma infiltrated with inflammatory cells.

FDG PET Findings according to Wandering Patterns of Patients with Drug-naïve Alzheimer's Disease

  • Yang, YoungSoon;Kwak, Yong Tae
    • 대한치매학회지
    • /
    • 제17권3호
    • /
    • pp.90-99
    • /
    • 2018
  • Background and Purpose: To explore anatomic substrate of specific wandering patterns in patients with Alzheimer's disease (AD) by performing positron emission tomography with $^{18}F$ fluorodeoxyglucose positron emission tomography (FDG PET). Methods: Drug-naïve AD patients with wandering (n=80) and without wandering (n=262) were recruited. First, the specific pattern of wandering type was operationally classified according to specific wandering score and clinical assessment. Second, brain FDG PET was performed and fluorodeoxyglucose (FDG) uptake differences of specific brain regions according to wandering patterns were compared to those of non-wanderers. Results: In patients with pacing pattern, FDG PET showed significant lower FDG uptake in both middle cingulum and left putamen cluster compared to non-wanderers. The right precuneus and supplementary motor area in patients with random pattern and left calcarine sulcus, right calcarine sulcus, right middle cingulum, and right post central gyrus in patients with lapping pattern had significantly lower FDG uptake compared to non-wanderers. Conclusions: This study showed that wandering in patients with AD had three distinct patterns. These specific patterns showed significant lower FDG uptake in specific brain areas compared to non-wanderers.

Prognostic Value of Restaging F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict 3-Year Post-Recurrence Survival in Patients with Recurrent Gastric Cancer after Curative Resection

  • Sung Hoon Kim;Bong-Il Song;Hae Won Kim;Kyoung Sook Won;Young-Gil Son;Seung Wan Ryu
    • Korean Journal of Radiology
    • /
    • 제21권7호
    • /
    • pp.829-837
    • /
    • 2020
  • Objective: The aim of this study was to investigate the prognostic value of the maximum standardized uptake value (SUVmax) measured while restaging with F-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) to predict the 3-year post-recurrence survival (PRS) in patients with recurrent gastric cancer after curative surgical resection. Materials and Methods: In total, 47 patients with recurrent gastric cancer after curative resection who underwent restaging with 18F-FDG PET/CT were included. For the semiquantitative analysis, SUVmax was measured over the visually discernable 18F-FDG-avid recurrent lesions. Cox proportional-hazards regression models were used to predict the 3-year PRS. Differences in 3-year PRS were assessed with the Kaplan-Meier analysis. Results: Thirty-nine of the 47 patients (83%) expired within 3 years after recurrence in the median follow-up period of 30.3 months. In the multivariate analysis, SUVmax (p = 0.012), weight loss (p = 0.025), and neutrophil count (p = 0.006) were significant prognostic factors for 3-year PRS. The Kaplan-Meier curves demonstrated significantly poor 3-year PRS in patients with SUVmax > 5.1 than in those with SUVmax ≤ 5.1 (3-year PRS rate, 3.5% vs. 38.9%, p < 0.001). Conclusion: High SUVmax on restaging with 18F-FDG PET/CT is a poor prognostic factor for 3-year PRS. It may strengthen the role of 18F-FDG PET/CT in further stratifying the prognosis of recurrent gastric cancer.

연속적인 FDG-PET/CT 검사에서 섭취 감소로 관찰된 비소세포암의 뇌전이 (Sequential Change of Hypometabolic Metastasis from Non-small-cell Lung Cancer on Brain FDG-PET/CT)

  • 박순아;양세훈;양충용;최금하
    • Nuclear Medicine and Molecular Imaging
    • /
    • 제43권5호
    • /
    • pp.505-507
    • /
    • 2009
  • A 60-year-old woman, who had non-small-cell lung cancer (NSCLC) in left lower lobe underwent brain F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for evaluation of cerebral metastasis. On follow-up FDG-PET/CT, only hypometaolic lesion was detected and progressed in right frontal lobe at 6 months and 10 months, later. Hypermetabolic metastasis was not detected even at last scan time of FDG-PET/CT. Brain MRI showed brain metastasis in right frontal lobe. As might be expected, the physician should take cerebral metastasis into consideration even though there is only hypometabolic change on subsequent FDG-PET/CT in patients with NSCLC.

$^{18}F$-FDG PET/CT 검사에서 이뇨제 사용여부에 따른 $^{18}F$-FDG 배설 특성 (Characteristic of $^{18}F$-FDG Excretion According to Use Diuretics in $^{18}F$-FDG of PET/CT)

  • 장동근;양승오;이상호;배종림;김정구
    • 대한방사선기술학회지:방사선기술과학
    • /
    • 제35권2호
    • /
    • pp.151-156
    • /
    • 2012
  • $^{18}F$-fluorodeoxyglucose ($^{18}F$-FDG)는 상당한 양의 방사능이 신장과 비뇨기계에 저류 되어 영상의 질을 저하시키고 진단 성능을 저하시킨다. 이러한 $^{18}F$-FDG의 비뇨기계 저류를 막기 위해 이뇨제를 사용하여 검사를 진행하게 된다. 이때 사용되는 이뇨제가 영상에 미치는 영향과 $^{18}F$-FDG 배설률에 미치는 영향을 알아보고자 하였다. PET/CT 검사를 시행한 환자 중 신장의 원발성 종양 또는 전이 병변이 없는 환자를 대상으로 $^{18}F$-FDG와 함께 이뇨제를 주사한 그룹, 생리식염수를 주사한 그룹, $^{18}F$-FDG만을 주사 한 정상군 그룹으로 진행하였으며, 각 그룹의 관심영역을 설정하여 SUV를 측정하였다. 또한 정량적 분석을 위하여 $^{18}F$-FDG를 주사 후 이뇨제 투여 여부에 따른 SUV를 비교 평가하였다. SUV 측정에 따라 영상의 배후방사능이 감소된 영상을 얻을 수 있었으며 이뇨제 사용으로 배설된 소변의 양이 늘어났지만, 소변에 방사능량의 변화가 없는 상반된 결과가 나타났다. 따라서 이뇨제가 영상의 배후방사능을 줄일 수는 있지만 $^{18}F$-FDG 배설에는 영향을 미치지 못함을 확인 하였다.

ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway

  • Sun, Tong;Du, Bulin;Diao, Yao;Li, Xuena;Chen, Song;Li, Yaming
    • BMB Reports
    • /
    • 제52권7호
    • /
    • pp.457-462
    • /
    • 2019
  • [18F]Fluorodeoxyglucose (FDG) PET/CT imaging has been widely used in the diagnosis of malignant tumors. ATPase family AAA domain-containing protein 2 (ATAD2) plays important roles in tumor growth, invasion and metastasis. However, the relationship between [18F]FDG accumulation and ATAD2 expression remains largely unknown. This study aimed to investigate the correlation between ATAD2 expression and [18F]FDG uptake in lung adenocarcinoma (LUAD), and elucidate its underlying molecular mechanisms. The results showed that ATAD2 expression was positively correlated with maximum standardized uptake value ($SUV_{max}$), total lesion glycolysis (TLG), glucose transporter type 1 (GLUT1) expression and hexokinase2 (HK2) expression in LUAD tissues. In addition, ATAD2 knockdown significantly inhibited the proliferation, tumorigenicity, migration, [18F]FDG uptake and lactate production of LUAD cells, while, ATAD2 overexpression exhibited the opposite effects. Furthermore, ATAD2 modulated the glycometabolism of LUAD via AKT-GLUT1/HK2 pathway, as assessed using LY294002 (an inhibitor of PI3K/AKT pathway). In summary, to explore the correlation between ATAD2 expression and glycometabolism is expected to bring good news for anti-energy metabolism therapy of cancers.